PALB2

New Releases

Premium

Myriad Genetics' Panexia Predictive Pancreatic Cancer Test

The company is planning to develop a new diagnostic test for early detection of pancreatic cancer by combining PALB2 gene mutations with mutations in the BRCA 2 gene and p16 genes, to which Myriad also holds exclusive rights under 10 issued US patents. The test is slated for launch in 2010.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.